Menu Search
Equities

Geron Corp

GON:FRA

Geron Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)3.90
  • Today's Change-0.045 / -1.14%
  • Shares traded700.00
  • 1 Year change+120.55%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:06 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Geron Corp's revenues fell -60.23% from 596.00k to 237.00k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 141.90m to a larger loss of 184.13m.
Gross margin63.00%
Net profit margin-15,990.60%
Operating margin-16,559.94%
Return on assets-50.78%
Return on equity-72.56%
Return on investment-63.77%
More ▼

Cash flow in USDView more

In 2023, Geron Corp increased its cash reserves by 24.35%, or 13.93m. Cash Flow from Financing totalled 362.02m or 152,751.48% of revenues. In addition the company used 167.74m for operations while cash used for investing totalled 180.32m.
Cash flow per share-0.3601
Price/Cash flow per share--
Book value per share0.5103
Tangible book value per share0.5103
More ▼

Balance sheet in USDView more

Geron Corp has a Debt to Total Capital ratio of 21.39%, a higher figure than the previous year's 13.67%.
Current ratio3.61
Quick ratio3.60
Total debt/total equity0.272
Total debt/total capital0.2139
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.